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1. SUMMARY OF PLANS FOR NEXT YEAR OF SUPPORT 
No significant changes are planned over those outlined in the original proposal. Specifically 
we will: 
A. Chemistry 
1. Complete all synthetic work related to the GBR series of aryl 
1,4-dialk(en)ylpiperazines. 
2. Complete all synthetic work related to the mazindol series of imidazo-isoindols. 
3. Continue synthetic work on the methylphenidate series. 
4. Start work on on the dopamine series or another new structure if appropriate. 
B. Pharmacology 
1. Complete all testing of the GBR series. 
2. Start and largely complete work on the mazindol series. 
3. Start work on the methylphenidate series. 
2. DESCRIPTION OF WORK CONDUCTED IN CURRENT YEAR (9/30/89 TO 11/30/90) 
A. Chemistry 
1. GBR Seri  
Synthetic work was initiated in this series using the methods outlined in the the literature 
with a number of significant modifications and additions. This work is summarized below: 
 
PA 	 Ph 
N•014 	-kelj4 Olt Chi. 




No2. 	 NO2. 	 Mou 
	1 
1-1 
4- Ph 	 "K 
	
N Ph 
ft' 	 i-4 
14 2 
PHS 2590 (Rev. 10/88) (Reprinted 9/89) 
	
PAGE 6 	 (Use continuation pages if necessary) 
Ph 
1 + 2 
3 R 1=NO2 , R2=H 
4 R 2=NO2 , R 1=H 
5 R 1=NH2 , R 2=H 7 R 1=N=C=S, R2=H 
6 R 2=NH2 , R 1=H 8 R2=N=C=S, R 1=H 




r-Ge Ph GHiel 
• COs0 	W  t p  
p- aPh 
1.1  Pee/Ns. 
11 R 1=NO21 R 2=H 
12 R2=NO2 , R 1=H 
13 R 1=NO2 , R2=H 
14 R2-NO2 , R 1=H 
5 or 6 
CS CI L 
 Na1}ea3(as ) 
ce3 
7 or 8 
7-) Ate o 
/Jac Ac. 
Li 10 R 2= N , R1=H 
0 
New compounds 3-10 have been synthesized, fully characterized and submitted for screening 
in the methylphenidate radioligand assay. These results are summarized in section B.2. 
2. Mazindol Series 
The Friedel-Crafts acylation of chlorobenzene with 4-nitrophthalic anhydride gives a 4:1 
mixture of the expected 5-nitro product (11) to the 4-nitro product (12). This mixture can be 
separated by crystallization. Condensation of 11 or 12 with ethylene diamine gives 13 or 14 which 
on reduction gives 15 or 16, respectively. Lithium aluminum hydride reduction of 15 or 16 does  
not give the expected products, but instead gives materials formulated as 17 or 18, respectively. 
Alternative methods to convert these to the desired final products are being explored. We have 
also synthesized the unsubstitued mazindol series 19-21, which will be screened. 
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3. Methvlohenidate Series 
The reaction of p-methoxyphenylacetonitrile with 2-bromopyridine according to the literature 
procedure gave a difficult to separate mixture from which the desired product (22) could be 
separated by chromatography in very low yield. After modification of the conditions, satisfactory 
yields (isolated by crystallization) were obtained as shown below. Partial hydrolysis of 22 gave 23 
which upon hydogenation gave 24 as a mixture of erythro (predominate) and threo isomers. 
Deprotection and isomerization of 24 was acheived in excellent yield using 48% HBr yielding 25 
in which the predominate threo isomer could be separated by crystallization. After convertion of 
threo 25 to the methyl ester (p-hydroxymethylphenidate) this compound will be screened before 
further work in undertaken. 
B. Pharacology 
1. Fourohit  
a. Biochemical studies. 
In vitro studies examining the effect of Fourphit on [ 3H]methylphenidate binding were 
completed. This isothiocyanate derivative of phencylidine was found to inhibit binding to the 
stimulant recognition site with an IC 50 of 7.1 AM (Fig.1). Washout studies (conducted under 
conditions where reversibly bound phencyclidine was completely removed) demonstrated that 
inactivation of the stimulant recognition site by Fourphit was irreversible, while inactivation of 
the phencyclidine receptor by the compound was reversible (Fig. 2). Partial protection of the 
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stimulant recognition site from inactivation by Fourphit was afforded by pretreatment of striatal 
tissue with saturating amounts of unlabeled methylphenidate, suggesting that the acylating 
compound may bind covalently to the receptor directly at the site recognized by methylphenidate, 
rather than allosterically (Table 1). Studies examining the effects of Fourphit on the dissociation 
rate of [ 3H]methylphenidate also supported the interpretation that the inhibition caused by 
Fourphit was not due to an allosteric interaction of the compound with the stimulant recognition 
site (Table 2). 
b. Behavioral studies. 
Intravenous injection of Fourphit (20 mg/kg) had little or no effect on the activity levels of 
rats. On the other hand, the activity levels of rats in response to a challenge with selected 
stimulant agents was altered by pretreatment with. Fourphit 24 hrs in advance, as compared to 
rats injected with vehicle alone one day prior to administration of the stimulant drugs. The 
effect of Fourphit on stimulant-induced locomotion was not constant, but appeared to vary with 
the respective stimulants. As predicted in the original proposal, Fourphit attenuated the 
hyperactivity induced by challenge with a low dose of cocaine (Fig. 3). Rats pretreated with 
Fourphit prior to challenge with methylphenidate (Ritalin), which belongs to the same class of 
stimulant agents as cocaine, however, showed no change (or possibly even a slight increase) in 
activity, compared to vehicle-pretreated control animals injected with methylphenidate (Fig. 4). 
Pretreatment with Fourphit significantly increased locomotor activity observed following low doses 
of d-amphetamine (0.8 and 1.25 mg/kg; Figs. 5 and 6, respectively), while it was without effect 
on the activation induced by 1.5 mg/kg of imethamphetamine (Fig. 7), which belongs to the same 
class of stimulant drugs as amphetamine. 
In vitro measurement of [ 3H]methylphenidate binding in striatal tissue dissected from the rats 
utilized in the behavioral studies described above revealed no consistent changes supportive of 
altered dopamine transport function. Future studies will examine binding of [ 3H]methylphenidate 
closer to the time of Fourphit administration, the hypothesis being that interference with uptake 
of dopamine occurring soon after injection of the phencyclidine derivative may lead to 
compensatory changes in dopamine uptake, metabolism, and/or release which differentially affect 
the animal's response to the various stimulant agents. 
2. GBR Serij 
The parent compound (GBR-12783) and intermediate 3 containing no reactive moiety were 
compared with 7 and 9 with respect to their effects on [ 3H]methylphenidate binding. A summary 
of the results is shown in Table 3. All of the compounds inhibited binding to the stimulant 
recognition site, with the following order of potency: GBR-12783> 3> 7> 9. The inhibition was 
marked by a Hill coefficient greater than one in all cases. Washout studies using a sodium-free 
solution for removing reversibly-bound compounds showed that only the isothiocyanate-substituted 
compound bound irreversibly to the stimulant recognition site. Future work will focus on 
characterization of the effect of 7 on [ 3H]methylphenidate binding, dopamine transport, and 
stimulant-induced behaviors. Initial screening of the other compounds in this series is planned for 
the immediate future, 
3. NO HUMAN SUBJECTS 
4. NO CHANGE IN THE USE OF ANIMALS (ASSURANCE #A1575) 
5. PUBLICATIONS: 
Manuscripts are in preparation concerning the effects of fourphit and the synthesis and 
pharmacology of the GBR compounds. 
Page 9 
100 
LL 80- 0 Z= 
Ow 














0A06305 - 02 
INHIBITION OF [3H]METHYLPHENIDATE 





Fig. I . Inhibition of [ 3JR]methylphenidate binding by Fourphit. 
Binding of [ 3II]methylphenidate was determined in samples containing 
aliquots of a P2 fraction suspended in Tris assay buffer and 
incubated for 30 min at 0°C with 7.6 nM [ 3H]methylphenidate and 
varying concentrations of Fourphit). Data shown are means ± SEM of 
triplicate samples from one experiment, which was repeated twice 
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Fig.iL . Effect of Fourphit on [ 3H]methylphenidate and [ 3H]TCP 
binding. In studies of [ 3ii]methylphenidate binding (open bars), a 
crude synaptosomal preparation of striatal tissue was reacted with 
28.6 uM Fourphit for 20 min at 0°C. In studies of [ 3H]TCP binding 
(hatched bars), tissue was reacted with 40 uM Fourphit for 30 min 
at 5 ° C. Binding in Fourphit-treated samples was compared with 
vehicle-treated controls before ("0 wash") and after removal of the 
drug-containing supernatant by repeated centrifugatioh and 
resuspension. Concentration of radioligand used to determine 
binding was 8.9 and 2 nM for Ofijmethylphenidate and [3H]TCP, 
respectively. Data shown are means of triplicate samples from one 
experiment, which was repeated twice more with similar results. 
For the data illustrated, the standard error of the mean ranged 
from 0.5 - 2.8%. 
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Table l. Protection by excess methylphenidate of the stimu-
lant recognition site from inactivation by Fourphit 
Percent inhibition of ['R]methylphenidate binding 
Tissue 









Inhibition of [ 3H]methylphenidate binding was determined before 
and after washing in samples (1) pretreated with 50 pM 
methylphenidate but not exposed to Fourphit ("Methylphenidate"); 
(2) not pretreated with methylphenidate, but exposed to 28.6 101 
Fourphit ("Fourphit"); and (3) pretreated with 50 pM 
methylphenidate before exposure to 28.6 pM Fourphit 
("Protected"). See Materials and Methods for experimental 
details. Control binding before and after washing was 61 ± 8 and 
46 ± 6 x 10 3 CPM's/mg protein, respectively (mean ± SEM from 
three separate experiments). Percent inhibition in protected 
samples after washing was calculated by comparison to the washed 
"Methylphenidate" samples; inhibition in all other samples was 
calculated by comparison to untreated controls. Significantly 
different from washed "Fourphit" (one-tailed paired t-test, 
P<0.015). 
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(min'') 	 k12 (miW1 ) 
1 	Vehicle 10 AM amfonelic acid 	0.714 ± 0.048 ,N=1. 	 •■■■ 
5 AM Fourphit 
	
10 AM amfonelic acid 	0.744 + 0.036 
2 	Vehicle 
	
100 AM methylphenidate 	1.22 ± 0.14 	0.281 + 0.025 
Vehicle 
	
200 AM Fourphit 
	
1.30 + 0.20 	0.126 + 0.045* 
In the first series of experiments, a P2 fraction was incubated with 9 nM [ 3H]methylphenidate 
and either vehicle or 5 uM Fourphit for 30 min before initiating dissociation with 10 uM 
amfonelic acid. At the end of the 30 min incubation period (but before the addition of the 
amfonelic acid), specific binding of [ 3H]methylphenidate to the Fourphit-treated samples was 
50.5 ± 5.5 % of that in the vehicle-treated samples. In the second series of experiments, 
samples were equilibrated with 9 nM [ 3H]methylphenidate for 30 min before initiating 
dissociation with either 100 AM methylphenidate or 200 AM Fourphit. See Materials and Methods 
for details. Dissociation rates were determined using the KINETICS program (Biosoft). Results 
shown are means ± SEM from three separate experiments; duplicate samples were run within each 
experiment. *Significantly different from k42 obtained using 100 AM methylphenidate to 














rig are 3 















0.00 1 	  
0 
	
20 	 40 
	
60 	 SO 
rm (zabizitar) 	
4( 
FOURPHIT EFFECT on RITALIN BEHAVIOR 












0 	 ao 	 40 	 00 	 00 
Tao (Wants.) 	 44_ ,-e 
FOURPHIT EFFECT on AMPHETAMINE BEHAVIOR 
Total Aativit, 




it re. 5— 
FOURPHIT EFFECT on AMPHETAMINE BEHAVIOR 
Total LottoIty 






F:c*g i4-rc 7 
FOURPHIT EFFECT ON METHAMPHETAMINE 
ashavior - Teta £otMty 
	







1 	0.50 1 0.4.0 1-1 • 








20 	 40 	 00 	 so 0 
(mlaustan) 
Figs. 3 - 7 . Rats were housed individually overnight. After 
injection with Fourphit (20 mg/kg, i.v.) or vehicle, they were 
returned to their home cages. Twenty-four hours later, they were 
challenged (i.p.) with a stimulant agent (cocaine, methylphenidate, 
amphetamine, or methamphetamine) or saline vehicle, the animals 
were returned to their home cages, and each individual cage was 
placed in an animal activity monitoring apparatus where activity 
was measured at 5 min intervals over a period of 60 min. (The 
activity was quantitated by counting the number of times the IR 
light beams were broken as the animal moved about the cage.) 
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TABLE 3. 	Effect of GBR-12783 and its derivatives on 
[3H]methylphenidate binding 
Compound ICso (nM) nH 
GBR-12783 12.1 + 1.3 2.7 
2HD7.3 39.3 + 4.7 1.7 
2HD16.3 493 	± 94 3.0 
2HD15.5 1677 + 412 1.8 
IC50 = concentration required to inhibit 8-10 nM 
[ 3H]methylphenidate binding by 50% when incubated for 30 min 
at 0°C. IC50 values are means + SEM derived grapically from 
three separate inhibition curves generated using 5-7 
different concentrations. nH me Hill coefficient; values 
shown are the average of two separate experiments conducted 
as described above. 
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